UBS: Eli Lilly's 'Outlook Continuing To Improve'

UBS on Monday issued a report on Eli Lilly and Co LLY. The firm rates Eli Lilly as Neutral with a one-year price target of $69.00.

Analyst Marc Goodman wrote , “Management has done a nice job getting through the difficult patent expiry period, and it appears that Lilly now has a good opportunity to put up low-to-mid teens EPS growth over the next 5 years, which should be near the best in the sector. But the stock at a P/E of almost 20x 2016E EPS also reflects this type of strong performance.”

In the short-term, Eli Lilly is expected to focus on vaccinations and execute deals that are more regional rather than global.

UBS estimate that Eli Lilly's 2015 EPS will be $3.15.

Eli Lilly has traded at $71.35 on Monday, down 0.90 percent.